| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 10g | |||
| Other Sizes |
Purity: ≥98%
Demeclocycline HCl (also known as demeclocycline hydrochloride; trade names: Detravis; Ledermycin), a protein translation inhibitor and potential calpain inhibitor, is a potent tetracycline antibiotic that inhibits the protein synthesis in bacteria, it is used for the treatment of bacterial infections. Demeclocycline is a semisynthetic tetracycline antibiotic which was derived from a strain of Streptomyces aureofaciens. Demeclocycline binds to bacterial 30S ribosomal subunit and prevents binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Demeclocycline also inhibits the effect of vasopressin on the renal tubules, thereby causing diuresis.
| Targets |
Tetracycline
Demeclocycline HCl targets antidiuretic hormone (ADH)-mediated water reabsorption pathway in renal collecting ducts [1][2][3] |
|---|---|
| ln Vitro |
Demeclocycline HCl (100 μM, 2 hours) inhibited ADH-induced water reabsorption by 65% in rat renal medullary slices, reducing tritiated water uptake compared to ADH-treated controls [2]
Demeclocycline HCl (50–200 μM) exhibited concentration-dependent inhibition of ADH-stimulated cyclic AMP (cAMP) accumulation in renal medullary tissue, with maximal inhibition at 150 μM (70% reduction) [2] |
| ln Vivo |
Demeclocycline HCl (600–1200 mg/day, oral administration for 7–14 days) normalized serum sodium levels in patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH): serum sodium increased from 125 ± 3 mmol/L to 138 ± 2 mmol/L, and urine output increased by 2–3-fold [1][3]
Demeclocycline HCl (20 mg/kg/day, oral for 5 days) induced nephrogenic diabetes insipidus in rats: 24-hour urine volume increased from 12 ± 2 mL to 45 ± 5 mL, and urine osmolality decreased from 1800 ± 150 mOsm/kg to 350 ± 40 mOsm/kg [2] Demeclocycline HCl (800 mg/day, oral) was superior to lithium carbonate (900 mg/day) in treating chronic SIADH: response rate was 85% vs. 50%, with fewer side effects (gastrointestinal upset in 10% vs. neurotoxicity in 30%) [3] |
| Cell Assay |
Renal water reabsorption assay: Rat renal medullary slices were prepared and incubated in buffer containing Demeclocycline HCl (50–200 μM) for 30 minutes, followed by addition of ADH (10 nM); tritiated water was added to the incubation system, and water uptake was quantified by liquid scintillation counting after 2 hours [2]
cAMP accumulation assay: Renal medullary tissue homogenates were treated with Demeclocycline HCl (50–200 μM) and ADH (10 nM) for 1 hour; cAMP levels were measured by radioimmunoassay to assess ADH signaling inhibition [2] |
| Animal Protocol |
Nephrogenic diabetes insipidus model: Sprague-Dawley rats were randomly divided into control and treatment groups; treatment group received Demeclocycline HCl (10–30 mg/kg/day, dissolved in saline) via oral gavage or intraperitoneal injection for 5 days; 24-hour urine volume and osmolality were measured daily, and renal tissue was collected for in vitro analysis [2]
|
| ADME/Pharmacokinetics |
Demeclocycline hydrochloride is well absorbed orally, with an oral bioavailability of approximately 80% in humans [1][3]. After oral administration of 300 mg, the peak plasma concentration (Cmax) is 4-6 μg/mL in 2-4 hours [1]. The plasma elimination half-life (t1/2) of this drug in adults is 12-16 hours, of which 60-70% is excreted unchanged in the urine [1][3]. This drug is widely distributed in various tissues, including the renal medulla (tissue/plasma ratio of 3.5 4 hours after administration) [2].
|
| Toxicity/Toxicokinetics |
Common side effects of demecycline hydrochloride include gastrointestinal discomfort (nausea, vomiting, diarrhea), with an incidence of approximately 10% to 15% [1][3]. Photosensitivity reactions (rash, erythema) occur in approximately 5% of patients, especially those who have been exposed to sunlight for extended periods [3].
|
| References |
|
| Additional Infomation |
Demeclocycline hydrochloride (oral) may cause developmental toxicity, depending on state or federal labeling requirements. Demeclocycline hydrochloride is the hydrochloride salt of demeclocycline. It is a tetracycline antibiotic primarily used in its hydrochloride form to treat Lyme disease, acne, and bronchitis, as well as hyponatremia (low blood sodium levels) caused by syndrome of dysregulation of antidiuretic hormone secretion (SIADH), especially when fluid restriction alone is ineffective. It has antibacterial and diuretic effects. It contains demeclocycline. Demeclocycline is a tetracycline analog with 7-chloro and 6-methyl groups. Because it is excreted more slowly than tetracycline, it maintains effective blood concentrations for a longer period. See also: Demeclocycline (note moved to) Demeclocycline hydrochloride (note moved to).
Demeclocycline hydrochloride is a semi-synthetic tetracycline antibiotic with additional pharmacological activity antagonizing antidiuretic hormone (ADH)-mediated water reabsorption[1][2][3] Its mechanism of action in syndrome of abnormal antidiuretic hormone secretion (SIADH) includes inhibiting ADH-induced accumulation of cAMP in the renal collecting ducts, reducing aquaporin-mediated water permeability, and inducing nephrogenic diabetes insipidus[2][3] It is indicated for the treatment of chronic syndrome of abnormal antidiuretic hormone secretion (SIADH) when fluid restriction is ineffective[1][3] It is superior to lithium carbonate in the treatment of SIADH due to its higher efficacy, faster onset of action (3-5 days vs. 7-10 days), and fewer serious side effects[3] As an antibiotic, it is active against both Gram-positive and Gram-negative bacteria, but its application in SIADH is unrelated to antibacterial activity[1] |
| Molecular Formula |
C21H21CLN2O8.HCL
|
|
|---|---|---|
| Molecular Weight |
501.31
|
|
| Exact Mass |
500.075
|
|
| Elemental Analysis |
C, 50.31; H, 4.42; Cl, 14.14; N, 5.59; O, 25.53
|
|
| CAS # |
64-73-3
|
|
| Related CAS # |
Demeclocycline;127-33-3
|
|
| PubChem CID |
54686764
|
|
| Appearance |
Solid powder
|
|
| Boiling Point |
795.9ºC at 760 mmHg
|
|
| Melting Point |
>245°C (dec.)
|
|
| Flash Point |
435.2ºC
|
|
| LogP |
1.767
|
|
| Hydrogen Bond Donor Count |
7
|
|
| Hydrogen Bond Acceptor Count |
9
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
33
|
|
| Complexity |
961
|
|
| Defined Atom Stereocenter Count |
5
|
|
| SMILES |
ClC1C([H])=C([H])C(=C2C(=C3C([C@@]4(C(=C(C(N([H])[H])=O)C([C@]([H])([C@]4([H])C([H])([H])[C@]3([H])[C@@]([H])(C2=1)O[H])N(C([H])([H])[H])C([H])([H])[H])=O)O[H])O[H])=O)O[H])O[H].Cl[H]
|
|
| InChi Key |
GVSJQNRGSCOSNJ-KBHRXELFSA-N
|
|
| InChi Code |
InChI=1S/C21H21ClN2O8.ClH/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31;/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31);1H/t6-,7-,14-,15-,21-;/m0./s1
|
|
| Chemical Name |
(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL ( ~199.47 mM )
Water : 33.33 ~40 mg/mL(~66.49 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.99 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View MoreSolubility in Formulation 3: font color= ‘FF0000’>10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.99 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9948 mL | 9.9739 mL | 19.9477 mL | |
| 5 mM | 0.3990 mL | 1.9948 mL | 3.9895 mL | |
| 10 mM | 0.1995 mL | 0.9974 mL | 1.9948 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02740933 | UNKNOWN | Drug: Demeclocycline | Brain Tumor | Massachusetts General Hospital | 2016-04 | Phase 1 |
| NCT02576652 | COMPLETED | Other:Tetracycline Other:Demeclocycline Procedure:Total Hip Replacement |
Osteoporosis | Amgen | 2015-12-22 | Phase 4 |
| NCT00873808 | WITHDRAWN | Drug:clodronate disodium Drug:demeclocycline hydrochloride Drug:ibandronate sodium |
Breast Cancer | SWOG Cancer Research Network |
2008-10 | |
| NCT01279187 | TERMINATED | Drug: Teriparatide | Implant | University of Michigan | 2011-02 | Phase 2 |
| NCT03960437 | COMPLETED | Drug: Etelcalcetide | Chronic Kidney Disease Mineral and Bone Disorder Hyperparathyroidism; Secondary, Renal Renal Osteodystrophy Vascular Calcification |
Thomas Nickolas, MD MS | 2018-09-06 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA